Postbiotics with immunity-enhancing function and preparation method and application thereof

Through the mixed bacteria fermentation method, the production of lactic acid bacteria EPS was improved by using the combination of lactic acid bacteria RH1729, lactic acid lactic acid RH2712, lactic acid plant HCS03-001, Lactobacillus fermented mucinous HCS08-005 and rhamnosus RH0131. It enhances immunity and solves the problem of low yield of extracellular polysaccharides in lactic acid bacteria.

CN118303634BActive Publication Date: 2024-11-15RENREN MICROBIAL TECH RES (SHENYANG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410305642.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-18
Publication Date
2024-11-15
Estimated Expiration
2044-03-18

AI Technical Summary

Technical Problem

In the existing methods, the yield of lactic acid bacteria extracellular polysaccharides is relatively low, making it difficult to meet the needs of industrial production.

Method used

The mixed bacteria fermentation method is adopted, including the combination of C. paracetamol RH1729, C. lactococcus RH2712, C. planta HCS03-001, Lactobacillus fermented mucus HCS08-005 and C. rhamnosus RH0131, through activation culture, first-grade and Secondary fermentation, sterilization and drying steps to increase the yield of lactic acid bacteria EPS.

Benefits of technology

It significantly increased the production of lactic acid bacteria EPS to reach 2303.18μg/mL, and promoted the phagocytosis effect of macrophages and enhanced immunity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118303634B_ABST
    Figure CN118303634B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of microorganisms, and in particular to a postbiotic with an immunity-enhancing function, and a preparation method and application thereof. The postbiotic of the present invention includes Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentum HCS08-005, and Lactobacillus rhamnosus RH0131. The preparation method is to activate 5 strains respectively, mix them for primary fermentation and secondary fermentation, sterilize, dry, collect and package the final fermentation liquid to obtain a postbiotic product. The postbiotic lactic acid bacteria of the present invention have a high content of exopolysaccharides, and can significantly promote the phagocytic efficacy of macrophages, providing technical support for improving immunity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of microorganisms, and in particular relates to postbiotics with the function of enhancing immunity, and a preparation method and application thereof. Background Art

[0002] Postbiotics is a general term for the bacterial components of probiotics that still retain the same active ingredients as live bacteria after being processed by heat treatment, physical treatment, high hydrostatic pressure treatment, freeze-drying, ultrasonic vibration, etc., including bacterial components and metabolites.

[0003] Lactic acid bacteria exopolysaccharides (EPS) are a class of carbohydrate compounds secreted by lactic acid bacteria outside the cell wall during their growth and metabolism and often penetrate into the culture medium. Some of them are attached to the cell wall of microorganisms to form capsules, called capsule polysaccharides; some enter the culture medium to form mucus, called mucus polysaccharides. They are all products of microbial adaptation to the environment. Lactic acid bacteria exopolysaccharides can give fermented dairy products a special texture and flavor, and play the role of a safe food additive. It may also become a good source of food-grade polysaccharides and is widely used in the thickening, stabilization, emulsification, gelling and water retention of various foods. At the same time, lactic acid bacteria EPS has a variety of physiological functions, including enhancing human immunity, inhibiting the adhesion of harmful bacteria, lowering blood pressure, anti-oxidation, anti-tumor, anti-ulcer, anti-virus and improving the intestinal microecological environment. Due to the unique physical, chemical and rheological properties of lactic acid bacteria EPS, it can be used as a thickener, stabilizer, emulsifier, gelling agent, filler and water-holding agent in food, medicine, petrochemical and biochemical products. Especially in the food field, lactic acid bacteria EPS can be used as a new natural food additive in fermented foods, thereby improving food texture, taste, rheological properties and flavor, while giving the product certain nutritional and health benefits. As a natural macromolecular active substance, lactic acid bacteria EPS has good immunogenicity in regulating the body's immunity. What is more noteworthy is that the source of lactic acid bacteria EPS is traceable and does not produce toxic side effects, making it an ideal natural immune adjuvant.

[0004] Microbial exopolysaccharides have special advantages in product structure, performance and production, such as large production, easy separation from bacteria, and industrial production through deep fermentation. Since lactic acid bacteria are food-grade industrial production bacteria, they are safer and more practical than other bacteria.

[0005] Although the functions and applications of exopolysaccharides produced by lactic acid bacteria are extensive, the existing methods have low yields. How to increase the yield of exopolysaccharides from lactic acid bacteria is the main problem currently faced. Summary of the invention

[0006] In order to solve the above problems, the present invention provides a mixed bacteria fermentation method, including Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus mucilaginosus HCS08-005 and Lactobacillus rhamnosus RH0131. The method can effectively increase the yield of lactic acid bacteria EPS.

[0007] In one aspect, the present invention provides a probiotic composition for enhancing immunity, wherein the probiotic composition comprises Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentum HCS08-005 and Lactobacillus rhamnosus RH0131;

[0008] The deposit number of the Lactobacillus paracasei RH1729 is CGMCC No.28243;

[0009] The deposit number of the Pediococcus acidilactici RH2712 is CGMCC No.25165;

[0010] The deposit number of the plant lactobacillus HCS03-001 is CGMCC No.16258;

[0011] The deposit number of the fermented mucus lactobacillus HCS08-005 is CGMCC No.16259;

[0012] The preservation number of the rhamnosus lactobacillus RH0131 is CGMCC No.28242.

[0013] In another aspect, the present invention provides a method for preparing the aforementioned probiotic composition postbiotic, the preparation method comprising the following steps:

[0014] S1. Activate and culture the strains respectively;

[0015] S2, inoculating the fermentation liquid of step S1 into a fermentation tank for primary fermentation of mixed strains;

[0016] S3, inoculating the fermentation liquid of step S2 into a fermentation tank for secondary fermentation of mixed strains;

[0017] S4, sterilization;

[0018] S5, drying;

[0019] S6. Powder collection.

[0020] Specifically, the inoculum volume of the activation culture in step S1 is 3-8%; the conditions of the activation culture are: 32-35° C., static culture.

[0021] More specifically, the end point OD of the activation culture is 600 It is 8.0-17.0.

[0022] Preferably, the inoculum volume ratio of the activation culture in step S1 is 5%; the conditions of the activation culture are: 33±0.5°C, static culture, the end point OD of the activation culture of Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentum HCS08-005, and Lactobacillus rhamnosus RH0131 600 They are 12.0-16.0, 12.0-16.0, 10.0-14.0, 6.0-10.0, and 6.0-10.0 respectively.

[0023] Further preferably, the end point OD of the activation culture of Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentum HCS08-005, and Lactobacillus rhamnosus RH0131 is 600 They are 14.0, 14.0, 12.0, 8.0 and 8.0 respectively.

[0024] Specifically, the volume ratio of the mixed strains in S2 is: Lactobacillus paracasei RH1729: Pediococcus acidilactici RH2712: Lactobacillus plantarum HCS03-001: Lactobacillus fermentans HCS08-005: Lactobacillus rhamnosus RH0131=3-5:2-3:2-3:2-3:1-2.

[0025] Preferably, the volume ratio of the mixed strains in S2 is: Lactobacillus paracasei RH1729: Pediococcus acidilactici RH2712: Lactobacillus plantarum HCS03-001: Lactobacillus mucilaginosus HCS08-005: Lactobacillus rhamnosus RH0131=3:2:2:2:1.

[0026] Specifically, in S2, the inoculation amount of the mixed strain in the primary fermentation is 3-8% by volume; the liquid volume of the fermentation tank is 40-80% by volume; and the fermentation conditions may be: stirring fermentation at 32-35°C.

[0027] Preferably, the inoculation amount of the primary fermentation in S2 is 5% by volume; the liquid volume of the fermentation tank is 40-80% by volume; and the fermentation conditions are: stirring fermentation at 33±0.2°C.

[0028] Specifically, the inoculation amount of the secondary fermentation in S3 is 3-5% by volume; the liquid volume of the fermentation tank is 40-80% by volume; and the fermentation conditions may be: stirring fermentation at 32-35°C.

[0029] Preferably, the inoculation volume of the secondary fermentation in S3 is 5% by volume; the liquid volume of the fermentation tank is 40-80% by volume; the fermentation conditions are: stirring fermentation at 33±0.2℃,

[0030] More specifically, the secondary fermentation endpoint OD in step S3 is 600 9.5-12.0

[0031] Preferably, the secondary fermentation endpoint OD in step S3 600 is 11.0.

[0032] Specifically, the sterilization conditions in step S4 may be: 90-100° C., 30-40 minn.

[0033] Preferably, the sterilization conditions in step S4 are: 95° C., 30 min.

[0034] Specifically, the drying in step S5 is spray drying.

[0035] More specifically, the spray drying temperature may be 195±5°C.

[0036] Preferably, the spray drying temperature is 195°C.

[0037] In yet another aspect, the present invention provides use of the aforementioned probiotic composition or preparation method in the preparation of postbiotics for enhancing immunity.

[0038] Specifically, the immunity enhancement includes but is not limited to promoting the phagocytic function of macrophages.

[0039] In yet another aspect, the present invention provides a postbiotic, wherein the postbiotic is obtained by using the aforementioned probiotic composition or preparation method.

[0040] The technical effects achieved by the present invention are:

[0041] (1) The content of postbiotic lactic acid bacteria EPS prepared by the present invention is high, up to 2303.18 μg / mL.

[0042] (2) The postbiotics prepared by the present invention can significantly promote the phagocytic effect of macrophages.

[0043] Storage Instructions 1:

[0044] Strain name: RH1729;

[0045] Deposit number: CGMCC No.28243;

[0046] Classification and nomenclature: Lacticaseibacillus paracasei;

[0047] Deposit date: August 24, 2023;

[0048] Depository: General Microbiology Center, China Microbiological Culture Collection Administration;

[0049] Address of the preservation unit: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.

[0050] Preservation Instructions 2:

[0051] Strain name: RH0131;

[0052] Deposit number: CGMCC No.28242;

[0053] Classification name: Lacticaseibacillus rhamnosus;

[0054] Deposit date: August 24, 2023;

[0055] Depository: General Microbiology Center, China Microbiological Culture Collection Administration;

[0056] Address of the preservation unit: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] Figure 1 This is a typical image of fluorescent particles in the zebrafish after sample treatment; the red fluorescent particles are fluorescent microspheres. DETAILED DESCRIPTION

[0058] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0059] Example 1

[0060] 1.1 Culture medium and strains

[0061] Culture medium (g / L): 20.0% anhydrous glucose; 10.0% yeast peptone; 5.0% yeast extract; 5.0% sodium acetate; 2.0% citric acid monohydrate; 2.0% potassium dihydrogen phosphate; 0.6% magnesium sulfate; and 0.25% manganese sulfate.

[0062] Strains:

[0063] Lactobacillus paracasei RH1729, deposited as CGMCC No.28243;

[0064] Pediococcus acidilactici RH2712, deposit number is CGMCC No.25165;

[0065] The deposit number of Lactobacillus plantarum HCS03-001 is CGMCC No.16258;

[0066] Lactobacillus mucilaginosus HCS08-005, deposit number is CGMCC No.16259;

[0067] Lactobacillus rhamnosus RH0131, the deposit number is CGMCC No.28242;

[0068] Lactobacillus paracasei HCS17-040, the deposit number is CGMCC No.19747;

[0069] Lactobacillus rhamnosus RH0121, the preservation number is CGMCC NO.26429.

[0070] Among them, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentans HCS08-005, Lactobacillus paracasei HCS17-040 and Lactobacillus rhamnosus RH0121 are all public strains and do not involve preservation certificates.

[0071] 1.2 Bacteria Activation

[0072] Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentans HCS08-005, and Lactobacillus rhamnosus RH0131 were inoculated into a triangular flask containing 10 mL of culture medium in a pure strain culture manner at a 5% (v / v) inoculation amount, and statically cultured at 33±0.5°C for 17.0±0.5h to obtain a bacterial suspension, wherein the fermentation endpoint OD of Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentans HCS08-005, and Lactobacillus rhamnosus RH0131 was 0.1447 W / m, 0.131 W / m, 0.171 W / m, 0.167 W / m, 0.171 W / m 600 They are 14.0, 14.0, 12.0, 8.0 and 8.0 respectively.

[0073] 1.3 Bacterial culture

[0074] 1.3.1 Primary fermentation:

[0075] The activated strains were mixed according to the addition ratio in Table 1, inoculated into the primary fermentation tank at an inoculum size of 5% (v / v), with a liquid volume of 40-80% (v / v), and stirred and fermented at 33±0.5°C, 100±2r / min (preferably 100r / min) for 17.0±0.5h.

[0076] Table 1

[0077] strains Addition ratio (v / v) Lactobacillus paracasei RH1729 30.0% Pediococcus acidilactici RH2712 20.0% Lactobacillus plantarum HCS03-001 20.0% Fermented Lactobacillus mucilaginosus HCS08-005 20.0% Lactobacillus rhamnosus RH0131 10.0%

[0078] 1.3.2 Secondary fermentation:

[0079] The bacterial liquid after primary fermentation was inoculated into the secondary fermentation tank at an inoculum volume of 5% (v / v), with a liquid volume of 40-80% (v / v), and stirred and fermented at 33±0.5℃, 100±2r / min (preferably 100r / min) for 48.0±0.5h. The fermentation end point OD 600 is 11.0.

[0080] 1.4 Sterilization

[0081] Sterilization parameters: 95℃, 30min.

[0082] 1.6 Drying

[0083] Spray drying, spray drying temperature is 195±5°C, preferably 195°C.

[0084] 1.7 Powder Collection

[0085] 1.8 Packaging and warehousing

[0086] Example 2 Detection of extracellular polysaccharides

[0087] The bacterial solution after secondary fermentation was taken and the EPS content of lactic acid bacteria was determined by phenol-sulfuric acid method. The reaction system was: the ratio of sample to 5% phenol and concentrated sulfuric acid was 1:1:5. Shake well and let stand at room temperature for 30 minutes. Use an enzyme marker to measure OD 490 nm value. 490 The content of lactic acid bacteria EPS can be calculated by substituting the nm value into the standard curve.

[0088] Result: 2303.18 μg / mL

[0089] Example 3 Zebrafish Functional Verification Test

[0090] 3.1 Maximum Detectable Concentration (MTC) Test for Immunity Enhancement

[0091] Zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO3), and were bred and provided by the Fish Farming Center of Hangzhou Huante Biotechnology Co., Ltd. The experimental animal use license number is: SYXK (Zhejiang) 2022-0004. The breeding and management complies with the requirements of the international AAALAC certification (certification number: 001458), and the IACUC ethics review number is: IACUC-2023-7775-01.

[0092] Wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 3 days post fertilization (3 dpf) were used for the MTC assay and efficacy evaluation of the sample's immunity enhancement efficacy.

[0093] The grouping and processing methods are as follows:

[0094] 3dpf wild-type AB strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. The lactic acid bacteria postbiotics group was given water-soluble lactic acid bacteria postbiotics at concentrations of 125μg / mL, 250μg / mL, 500μg / mL, 1000μg / mL and 2000μg / mL, and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. Except for the normal control group, the remaining experimental groups were intravenously injected with vinorelbine tartrate injection to establish a zebrafish immunodeficiency model. After treatment at 28℃ for 96h, the MTC of zebrafish with the efficacy of lactic acid bacteria postbiotics in enhancing immunity was determined.

[0095] As shown in Table 2, under the experimental conditions, the efficacy of lactic acid bacteria postbiotics on enhancing immunity in zebrafish MTC was 500 μg / mL.

[0096] Table 2 Results of the maximum detection concentration test for the efficacy of samples in enhancing immunity (n=30)

[0097]

[0098] 3.2 Immunity enhancement efficacy test

[0099] 3.2.1 Reagents and materials

[0100] Bailing Capsules (hereinafter referred to as Bailing Capsules), batch number 2111064, Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd., stored in a cool and dry place. Prepared into 15.0 mg / mL stock solution with standard dilution water, stored at 4°C.

[0101] Vinorelbine tartrate injection (Batch No. 190401, Jiangsu Hausen Pharmaceutical Co., Ltd., China); Sodium chloride injection (Batch No. S21091609, Hunan Kelun Pharmaceutical Co., Ltd., China); Methylcellulose (Batch No. C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Fluorescent microspheres (Batch No. MKCB2036V, SIGMA, USA).

[0102] 3.2.2 Experimental methods

[0103] 3dpf wild-type AB strain zebrafish were randomly selected in 6-well plates, and 30 zebrafish were treated in each well. The lactic acid bacteria postbiotics group was given water-soluble lactic acid bacteria postbiotics at concentrations of 125μg / mL, 250μg / mL and 500μg / mL, respectively, and the positive control group was given Bailing capsules at a concentration of 15.0μg / mL. At the same time, a normal control group and a model control group were set up, and the capacity of each well was 3mL. Except for the normal control group, the remaining experimental groups were intravenously injected with vinorelbine tartrate injection and fluorescent microspheres to establish a zebrafish immunodeficiency model. The normal control group was only injected with fluorescent microspheres. After 96h of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The Image-J image processing software was used to analyze and collect data, and the number of remaining fluorescent particles in the zebrafish was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of the samples in enhancing immunity.

[0104] As shown in Table 3 and Figure 1 As shown, under the experimental conditions, lactic acid bacteria postbiotics have the effect of promoting macrophage phagocytosis.

[0105] Table 3. Results of the experimental evaluation of the efficacy of lactic acid bacteria postbiotics in enhancing immunity (n=10)

[0106]

[0107] Compared with the model control group, **p<0.01, ***p<0.001

[0108] Comparative Example

[0109] The differences from Example 1 are shown in Table 4. The rest is the same as Example 1, and the extracellular polysaccharide detection is performed with reference to Example 2.

[0110] Table 4

[0111]

[0112] The experimental results are shown in Table 5:

[0113] Table 5

[0114]

[0115]

[0116] As shown in Table 5, after replacing, deleting, or changing the proportion of the lactic acid bacteria in the examples, the EPS was greatly reduced, indicating that the technical solution of the present invention has a synergistic effect.

Claims

1. A postbiotic for enhancing immunity, characterized in that: The postbiotics are prepared by a probiotic composition; the probiotic composition includes Lactobacillus paracasei RH1729, Pediococcus acidilactici RH2712, Lactobacillus plantarum HCS03-001, Lactobacillus fermentum HCS08-005 and Lactobacillus rhamnosus RH0131; The deposit number of the Lactobacillus paracasei RH1729 is CGMCC No. 28243; The deposit number of the Pediococcus acidilactici RH2712 is CGMCC No.25165; The deposit number of the plant lactobacillus HCS03-001 is CGMCC No.16258; The deposit number of the fermented mucus lactobacillus HCS08-005 is CGMCC No.16259; The deposit number of the Lactobacillus rhamnosus RH0131 is CGMCC No. 28242; The preparation method of the postbiotics comprises the following steps: S1. Activate and culture the strains respectively; S2, inoculating the fermentation liquid of step S1 into a fermentation tank for primary fermentation of mixed strains; S3, inoculating the fermentation liquid of step S2 into a fermentation tank for secondary fermentation of mixed strains; S4, sterilization; S5, drying; S6, powder collection; The volume ratio of the mixed strains in step S2 is: Lactobacillus paracasei RH1729: Pediococcus acidilactici RH2712: Lactobacillus plantarum HCS03-001: Lactobacillus fermentative mucus HCS08-005: Lactobacillus rhamnosus RH0131=3-5:2-3:2-3:2-3:1-2.

2. The postbiotic according to claim 1, characterized in that The inoculum volume of the activation culture in step S1 is 3-8% by volume, and the activation culture conditions are: 32-35° C., static culture.

3. The postbiotic according to claim 2, characterized in that The end point OD of the activation culture 600 It is 8.0-17.

0.

4. The postbiotic according to claim 1, characterized in that The inoculation amount of the mixed strain in the primary fermentation and the secondary fermentation in steps S2 and S3 is 3-8% by volume; the liquid volume of the fermentation tank is 40-80% by volume; and the fermentation conditions are: stirring fermentation at 32-35°C.

5. The postbiotic according to claim 4, characterized in that The secondary fermentation endpoint OD in step S3 600 It is 9.5-12.

0.

6. The postbiotic according to any one of claims 1 to 5, characterized in that The sterilization conditions in step S4 are: 90-100° C., 30-40 min; the drying in step S5 is spray drying.

7. Use of the probiotic composition of claim 1 in preparing postbiotics for enhancing immunity.